The following four neurological products are likely to reach market next year. Carving out sales will be an entirely different problem. 

Diabetes and obesity products like Ozempic/Wegovy and Mounjaro are gaining share at the expense of metformin and SGLT-2 inhibitors. Scrip looks at data on prescription shifts in the US while examining if metformin remains attractive and whether a recent study showing efficacy in long COVID treatment could help

Amgen's Prolia appears to be the biggest drug on the list of products incurring price inflation penalties in Part B; many of the others have relatively low sales to Medicare.

Sales of a global first-in-class dermatology drug that gained its first approval in China are falling well behind those of its overseas counterpart. Brian Yang takes a deeper look into the multiple underlying factors determining success in the world's second-largest pharma market beyond pricing and reimbursement coverage, including complex hospital entry, dual channels and competition considerations.